Geduld wird sich auszahlen.
|
Zahlen für Q3/23
- Acimtamig (also known as AFM13) combination with AlloNK® (also known as AB-101): Initiated LuminICE-203. Company on track to report initial data in H1 2024
- AFM24 combination with atezolizumab: On track to report data from three expansion cohorts in December 2023
- Cash runway into 2025
www.affimed.com/...sults-and-highlights-operational-progress/
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
6 | 1.591 | Affimed Therapeutics B.V. - AFMD | NikGol | elmario1 | 24.04.24 10:13 | |
3 | Affimed | BICYPAPA | Ulrich56 | 22.02.23 19:03 |